Platinum-based regimens play an essential role in triple-negative breast cancer (TNBC) treatment, with the CBCSG006 study establishing the position of gemcitabine plus cisplatin (GP) as a first-line treatment of metastatic TNBC. Our study aims to further improve the efficacy of the first-line platinum-based chemotherapy for metastatic TNBC by optimizing the selection of platinum.
Platinum-based regimens play an essential role in triple-negative breast cancer (TNBC) treatment, with the CBCSG006 study establishing the position of gemcitabine plus cisplatin (GP) as a first-line treatment of metastatic TNBC. Our study aims to further improve the efficacy of the first-line platinum-based chemotherapy for metastatic TNBC by optimizing the selection of platinum.